A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Subjects With Relapsed/Refractory Myelodysplastic Syndromes (MDS)



Status:Recruiting
Conditions:Blood Cancer, Blood Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:3/8/2019
Start Date:March 7, 2017
End Date:August 4, 2020
Contact:ABBVIE CALL CENTER
Email:abbvieclinicaltrials@abbvie.com
Phone:847.283.8955

Use our guide to learn which trials are right for you!

A Phase 1b Study Evaluating the Safety and Pharmacokinetics of Venetoclax as a Single-Agent and in Combination With Azacitidine in Subjects With Relapsed/Refractory Myelodysplastic Syndromes

This is a Phase 1b, open-label, multicenter study designed to evaluate the safety and
pharmacokinetics of venetoclax as a single-agent and in combination with azacitidine in
participants with relapsed/refractory Myelodysplastic Syndromes (MDS).


Inclusion Criteria:

- Subjects who have relapsed or refractory MDS.

- Subject enrolled in venetoclax monotherapy must have documented failure of prior
therapy with a hypomethylating agent (HMA). HMA-failure is defined as:

1. Relapse after initial complete or partial response or hematological improvement
after at least 4 cycles of azacitidine or at least 4 cycles of decitabine within
the last 5 years, OR

2. Failure to achieve complete or partial response or hematological improvement
after at least 4 cycles of azacitidine or at least 4 cycles of decitabine within
the last 5 years

- Subjects must have presence of < 20% bone marrow blasts per bone marrow
biopsy/aspirate at screening.

- Subject is not a candidate to undergo allogenic hematopoietic stem cell
transplantation (HSCT).

- Subject must have an Eastern Cooperative Oncology Group (ECOG) performance score of
≤2.

- Subject must have adequate hematologic, renal, and hepatic function.

Exclusion Criteria:

- Subject has received prior therapy with a BH3 mimetic.

- Subject has MDS evolving from a pre-existing myeloproliferative neoplasm (MPN).

- Subject has MDS/MPN including chronic myelomonocytic leukemia (CMML), atypical chronic
myeloid leukemia (CML), juvenile myelomonocytic leukemia (JMML) and unclassifiable
MDS/MPN.

- Subject has received allogeneic HSCT or solid organ transplantation.

- Subject has received a live attenuated vaccine within 4 weeks prior to the first dose
of study drug.

- Subject is pregnant or breastfeeding.
We found this trial at
11
sites
Aurora, Colorado 80045
?
mi
from 91732
Aurora, CO
Click here to add this to my saved trials
Boston, Massachusetts 02114
?
mi
from 91732
Boston, MA
Click here to add this to my saved trials
Boston, Massachusetts 02215
2576
mi
from 91732
Boston, MA
Click here to add this to my saved trials
5801 South Ellis Avenue
Chicago, Illinois 60637
1730
mi
from 91732
Chicago, IL
Click here to add this to my saved trials
Houston, Texas 77030
?
mi
from 91732
Houston, TX
Click here to add this to my saved trials
Kogarah, New South Wales
?
mi
from 91732
Kogarah,
Click here to add this to my saved trials
New Haven, Connecticut 06510
?
mi
from 91732
New Haven, CT
Click here to add this to my saved trials
2435
mi
from 91732
New York, NY
Click here to add this to my saved trials
?
mi
from 91732
Portland, OR
Click here to add this to my saved trials
1501 North Campbell Avenue
Tucson, Arizona 85724
427
mi
from 91732
Tucson, AZ
Click here to add this to my saved trials
Worcester, Massachusetts 01655
?
mi
from 91732
Worcester, MA
Click here to add this to my saved trials